 |
424 Diseases |  |
807 Trials |
|
807 Trials |  |
14372 News |  |
| «12...2627282930313233343536...235236» |
- | Keytruda (pembrolizumab) / Merck (MSD)
Trial completion date, Trial primary completion date: Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer (clinicaltrials.gov) - Dec 31, 2023
P2, N=3, Recruiting, Sponsor: Icahn School of Medicine at Mount Sinai
- | Erbitux (cetuximab) / Eli Lilly
Trial completion date, Metastases: FIRE-4: Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab (clinicaltrials.gov) - Dec 31, 2023
P3, N=673, Active, not recruiting, Sponsor: Ludwig-Maximilians - University of Munich
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
A Chemoresistance Signature to Predict FOLFIRINOX Sensitivity in Pancreatic Adenocarcinoma () - Dec 29, 2023 - Abstract #SSO2024SSO_412;
In addition, our findings support targeting the G2M checkpoint and E2F pathways to potentially counteract FFX resistance in PDAC patients. Learning Objectives: Upon completion, participant will be able to understand the need for improving chemotherapy treatment strategies for pancreatic cancer.
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Highly Sensitive Low Input Methylated Digital Droplet PCR Assay for Pancreatic Adenocarcinoma Molecular Subtyping () - Dec 29, 2023 - Abstract #SSO2024SSO_408;
ddPCR is a powerful, high sensitivity, lower cost technology offering clinical promise for the early detection and disease monitoring for many cancers, and it is already FDA approved for CML treatment response monitoring. Here we show our ability to predict subtype using only 14 nanograms of DNA on a ddPCR platform, >10 fold less required than Nanostring and >70 fold less than RNA sequencing.
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Postoperative Complications Following Neoadjuvant Therapy and Surgery in a Phase 2 Borderline Resectable Pancreatic Cancer Clinical Trial (Alliance A021501) () - Dec 29, 2023 - Abstract #SSO2024SSO_405;
Multimodality trials of preoperative therapy for locoregionally advanced pancreatic cancer may be safely performed in the cooperative group setting. Learning Objectives: 1.
- SX-682 / Syntrix
An Update On The Phase I Study to Evaluate the Safety and Tolerability of SX-682 in Combination with Anti-PD1 as Maintenance Therapy for Unresectable Pancreatic Adenocarcinoma () - Dec 29, 2023 - Abstract #SSO2024SSO_403;
P1
Clinical translation of this immunotherapy strategy is underway. At the time of submission there have been two DLTs.
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Combination of tumor and CAF subtypes better predict response to neoadjuvant therapy in pancreatic cancer () - Dec 29, 2023 - Abstract #SSO2024SSO_401;
Better locoregional response to systemic therapy may lead to better overall survival in these subtypes. Molecular subtyping of PDAC for both the tumor and tumor microenvironment may be important steps in selecting first-line therapy for patients with this deadly disease.
- 5-fluorouracil / Generic mfg.
Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) for Peritoneal Metastasis from Gastrointestinal Malignancy: Evaluation of Treatment Response in a Single Tertiary Center () - Dec 29, 2023 - Abstract #SSO2024SSO_186;
Further work is needed to define the optimal endpoints for randomized trials and assess correlation with survival and quality of life. Learning Objectives: Describe clinical tools for evaluation of treatment response to PIPAC.
- ||| Lonsurf (trifluridine/tipiracil) / Otsuka
Enrollment change: ERASE-CRC: Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients (clinicaltrials.gov) - Dec 29, 2023
P2, N=477, Recruiting, Sponsor: Gruppo Oncologico del Nord-Ovest
Learning Objectives: Describe clinical tools for evaluation of treatment response to PIPAC. N=300 --> 477
- | leucovorin calcium / Generic mfg.
New P1 trial: Vitamin B12 and Folinic Acid Supplementation in Mitochondrial DNA Deletion Syndromes (clinicaltrials.gov) - Dec 29, 2023
P1, N=25, Not yet recruiting, Sponsor: University of British Columbia
- | 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Journal, Real-world evidence, Real-world, Metastases: Hepatic arterial infusion therapy for advanced hepatocellular carcinoma after systemic treatment failure: A multi-center, real-world study. (Pubmed Central) - Dec 28, 2023
N=300 --> 477 Our findings support the effectiveness and safety of HAIC-FOLFOX treatment for patients with advanced HCC who have failed systemic treatment.
- | Avastin (bevacizumab) / Roche, Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
New P2 trial, Metastases: Liposomal Irinotecan and Leucovorin/5-fluorouracil Plus Bevacizumab in Metastatic Colorectal Cancer (clinicaltrials.gov) - Dec 28, 2023
P2, N=50, Not yet recruiting, Sponsor: Hebei Medical University Fourth Hospital
- |||| Avastin (bevacizumab) / Roche, Vectibix (panitumumab) / Amgen
Trial primary completion date: CR-SEQUENCE: Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal Cancer (clinicaltrials.gov) - Dec 27, 2023
P3, N=419, Active, not recruiting, Sponsor: Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Our findings support the effectiveness and safety of HAIC-FOLFOX treatment for patients with advanced HCC who have failed systemic treatment. Trial primary completion date: Jun 2024 --> Jun 2025
- || Trial completion date, Trial primary completion date: OPRA: Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Management (clinicaltrials.gov) - Dec 27, 2023
P2, N=358, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: Jun 2024 --> Jun 2025 Trial completion date: Nov 2023 --> Nov 2024 | Trial primary completion date: Nov 2023 --> Nov 2024
- | Observational data, Journal, Real-world evidence, Real-world, Metastases: Real-World Outcomes of First-Line FOLFIRI Plus Bevacizumab with Irinotecan Dose Escalation versus FOLFOXIRI Plus Bevacizumab in BRAF-Mutant Metastatic Colorectal Cancer: The Preliminary Data from a Single-Center Observational Study. (Pubmed Central) - Dec 27, 2023
This regimen leads to acceptable clinical outcomes with manageable AEs. However, the effects on survival and safety outcomes could only be speculated, and further studies are needed because of the sample size, the follow-up for the OS evaluation, and the non-uniformity in all the variables considered in the two groups.
- | elimusertib (BAY 1895344) / Bayer
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines (clinicaltrials.gov) - Dec 27, 2023
P1, N=90, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
However, the effects on survival and safety outcomes could only be speculated, and further studies are needed because of the sample size, the follow-up for the OS evaluation, and the non-uniformity in all the variables considered in the two groups. Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
- ||| IMM-1-104 / Immuneering
Enrollment change, Metastases: IMM1104-101: A Phase 1/2a Study of IMM-1-104 in Participants With Previously Treated, RAS-Mutant, Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Dec 27, 2023
P1/2, N=210, Recruiting, Sponsor: Immuneering Corporation
Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024 N=156 --> 210
- paclitaxel / Generic mfg., irinotecan / Generic mfg., gemcitabine / Generic mfg.
Real-world comparison of overall survival in patients with unresectable hepatocellular carcinoma treated with Folfirinox or Gemcitabine-Paclitaxel (ePoster Area) - Dec 26, 2023 - Abstract #LCS2024LCS_134;
For practitioners considering FOLFIRINOX therapy, there may not be strong justification for tolerating worse side effects compared to gemcitabine-paclitaxel. Further studies are needed to confirm these findings and to identify the optimal chemotherapy regimen for this patient population.
- | Enrollment closed, Trial completion date, Trial primary completion date: Neoadjuvant RCT Versus CT for Patients With Locally Advanced, Potentially Resectable Adenocarcinoma of the GEJ (clinicaltrials.gov) - Dec 26, 2023
P3, N=342, Active, not recruiting, Sponsor: Universit
Further studies are needed to confirm these findings and to identify the optimal chemotherapy regimen for this patient population. Recruiting --> Active, not recruiting | Trial completion date: Aug 2028 --> Dec 2025 | Trial primary completion date: May 2028 --> Dec 2025
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Journal: Suppression of the KRAS-NRF2 axis shifts arginine into the phosphocreatine energy system in pancreatic cancer cells. (Pubmed Central) - Dec 25, 2023
Inhibition of the creatine pathway with cyclocreatine reduced both ATP and invasion rate in 3D spheroids from NRF2-deficient PDAC cells. Our study provides basis for the rational development of combination therapies for pancreatic cancer.
- | 5-fluorouracil / Generic mfg.
Journal: 5-Fluorouracil-associated severe hypertriglyceridaemia with positive rechallenge. (Pubmed Central) - Dec 24, 2023
We here report the case of a patient who developed 5-FU-associated grade 4 HTG with TG level raising up to 37.1?mmol/L (3286?mg/dL) occurring after the ninth cycle of adjuvant FOLFOX (Fluorouracil and Oxaliplatin) chemotherapy...Chemotherapy was therefore permanently stopped. Approximately 8 weeks after chemotherapy discontinuation, TG fell back to range at 2.1?mmol/L (189?mg/dL) allowing interruption of fenofibrate without HTG recurrence at 3 months.
- | 5-fluorouracil / Generic mfg.
Preclinical, Journal: Multisite Is Superior to Single-Site Intratumoral Chemotherapy to Retard the Outcomes of Pancreatic Ductal Adenocarcinoma in a Murine Model. (Pubmed Central) - Dec 23, 2023
Approximately 8 weeks after chemotherapy discontinuation, TG fell back to range at 2.1?mmol/L (189?mg/dL) allowing interruption of fenofibrate without HTG recurrence at 3 months. Multisite intratumoral therapy in tandem with systemic treatment holds promise for reducing the tumor size and enhancing the overall survival in LAPC.
- | Journal, Metastases: The Impact of BRAF Mutation Status on Survival Outcomes and Treatment Patterns among Metastatic Colorectal Cancer Patients in Alberta, Canada. (Pubmed Central) - Dec 23, 2023
Mutant BRAF patients had a median survival of 8.21 months compared to 20.03 months among those with wild-type BRAF. BRAF mutations among mCRC patients are associated with a considerably poor prognosis, reinforcing the need for clinical BRAF testing among newly diagnosed patients to better understand their prognosis.
- | leucovorin calcium / Generic mfg.
Journal: Cerebral folate deficiency: a treatable cause of late deterioration in epilepsy with developmental delay. (Pubmed Central) - Dec 23, 2023
Following antiseizure medication adjustment and treatment with folinic acid, she stabilised with improved seizure control and limited improvement in language and motor function; she has remained neurologically stable for more than a decade...Metabolic conditions are less well recognised in adults and can be under-diagnosed. They are potentially treatable and should be considered even in the presence of another cause, particularly when the presentation is not fully compatible.
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
P2 data, Journal, Metastases: Stereotactic MR-guided on-table adaptive radiation therapy (SMART) for borderline resectable and locally advanced pancreatic cancer: a multi-center, open-label phase 2 study. (Pubmed Central) - Dec 23, 2023
P2
Long-term outcomes from the phase 2 SMART trial demonstrate encouraging OS and limited severe toxicity. Additional prospective evaluation of this novel strategy is warranted.
- | leucovorin calcium / Generic mfg., methotrexate / Generic mfg.
Journal: Folinic Acid Over: Rescue of Intermediate Dose Methotrexate. (Pubmed Central) - Dec 23, 2023
Additional prospective evaluation of this novel strategy is warranted. No abstract available
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Journal: Precision medicine for KRAS wild-type pancreatic adenocarcinomas. (Pubmed Central) - Dec 22, 2023
KRAS patients display distinct disease characteristics and outcomes with prolonged overall survival. KRAS patients also harbor more actionable molecular alterations, leading to higher survival rates after receiving molecularly matched treatments.
- || Keytruda (pembrolizumab) / Merck (MSD)
Trial completion date: KEYNOTE-585 China Extension study: Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension (clinicaltrials.gov) - Dec 22, 2023
P3, N=120, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
KRAS patients also harbor more actionable molecular alterations, leading to higher survival rates after receiving molecularly matched treatments. Trial completion date: Feb 2024 --> May 2024
- | Avastin (bevacizumab) / Roche
Enrollment closed, Trial completion date, Trial primary completion date: CLavSyn: Chemotherapy Intensification in Patients With High Lactate Dehydrogenase Values and Soluble Syndecan1 Levels (clinicaltrials.gov) - Dec 22, 2023
P2, N=177, Active, not recruiting, Sponsor: Centre Hospitalier Universitaire de Besancon
Trial completion date: Feb 2024 --> May 2024 Recruiting --> Active, not recruiting | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2024
- | Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
Trial primary completion date, Metastases: NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer (clinicaltrials.gov) - Dec 21, 2023
P2, N=44, Recruiting, Sponsor: Georgetown University
Recruiting --> Active, not recruiting | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2024 Trial primary completion date: Nov 2023 --> May 2024
- | Avastin (bevacizumab) / Roche
Retrospective data, Journal, Metastases: Efficacy of mFOLFOX6 plus bevacizumab regimen in advanced colorectal cancer after deep hyperthermia: a single-center retrospective study. (Pubmed Central) - Dec 21, 2023
mFOLFOX6 plus bevacizumab after deep hyperthermia is effective in advanced colorectal cancer patients, which can effectively improve their quality of life, and the adverse events are controllable and tolerable. A randomized or prospective trial will be required to further prove these data and explore its potentiality, especially if compared to conventional treatment.
- | Graspa (eryaspase) / PHAXIAM Therap
Trial completion date: Eryaspase With Modified FOLFIRINOX in Advanced Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov) - Dec 20, 2023
P1, N=19, Active, not recruiting, Sponsor: Georgetown University
A randomized or prospective trial will be required to further prove these data and explore its potentiality, especially if compared to conventional treatment. Trial completion date: Dec 2023 --> Jul 2024
- || Opdivo (nivolumab) / BMS
Trial completion date: RELATIVITY-060: An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers (clinicaltrials.gov) - Dec 20, 2023
P2, N=274, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Trial completion date: Dec 2023 --> Jul 2024 Trial completion date: Dec 2024 --> Jan 2024
- | Avastin (bevacizumab) / Roche, AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial, Metastases: FOBECAMS: Efficacy and Safety of Combined With Immunotherapy After Induction Therapy With Chemotherapy and Targeted Therapy in the First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer (clinicaltrials.gov) - Dec 20, 2023
P2, N=36, Recruiting, Sponsor: yue junhan
- || Bavencio (avelumab) / EMD Serono, Herceptin (trastuzumab) / Roche
Trial completion: Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas (clinicaltrials.gov) - Dec 19, 2023
P2, N=18, Completed, Sponsor: Ashwin Somasundaram
Trial completion date: Dec 2024 --> Jan 2024 Active, not recruiting --> Completed
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Immuno-molecular modulation in pancreatic cancer following isotoxic high-dose stereotactic body radiotherapy (iHD-SBRT). (Teun - Hilton Antwerp Old Town) - Dec 19, 2023 - Abstract #BWG2024BWG_177;
Methods Paraffin-embedded residual tumoral tissues of 50 localized PDAC resected between 2011 and 2020 were used: seventeen patients had surgery first, seventeen received an induction chemotherapy with FOLFIRINOX (FFX) only and sixteen with FFX followed by an iHD-SBRT designed to individually maximize the dose prescribed to the tumor and vessels interfaces up to Dmax(0.5cc)<lt;53Gy in 5 fractions...Despite an increase in collagen deposit, the global lymphocyte infiltration is preserved after iHD-SBRT. We also identified several increased pro-tumoral cells and pathways after iHD-SBRT that could improve the development of better-oriented combination trials involving high-dose SBRT.
- | 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Journal: The moderating role of circadian gene polymorphisms in the relationship between sleep disturbance and circulating lymphocyte subsets in colorectal cancer patients. (Pubmed Central) - Dec 19, 2023
Patients with specific circadian gene allele types may be more susceptible to immune dysregulation when experiencing sleep disturbances. Considering that sleep disturbance is a modifiable factor that can impact immune regulation, it is essential to prioritise the management of sleep disturbances in CRC patients receiving FOLFOX chemotherapy.
- | Avastin (bevacizumab) / Roche
Biomarker, Trial completion date, Trial primary completion date: Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer (clinicaltrials.gov) - Dec 19, 2023
P3, N=3610, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Considering that sleep disturbance is a modifiable factor that can impact immune regulation, it is essential to prioritise the management of sleep disturbances in CRC patients receiving FOLFOX chemotherapy. Trial completion date: Dec 2023 --> Mar 2024 | Trial primary completion date: Dec 2023 --> Mar 2024
- | Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
Enrollment closed, Trial completion date, Trial primary completion date: GIANT: Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread (clinicaltrials.gov) - Dec 19, 2023
P2, N=176, Active, not recruiting, Sponsor: ECOG-ACRIN Cancer Research Group
Trial completion date: Dec 2023 --> Mar 2024 | Trial primary completion date: Dec 2023 --> Mar 2024 Recruiting --> Active, not recruiting | Trial completion date: Dec 2023 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2025
- | 5-fluorouracil / Generic mfg.
Journal, Surgery, Metastases: Nationwide Use and Outcome of Surgery for Locally Advanced Pancreatic Cancer Following Induction Chemotherapy. (Pubmed Central) - Dec 18, 2023
Resection of LAPC following chemo(radio)therapy is infrequently performed in the Netherlands, albeit with acceptable morbidity, mortality, and OS. Given these findings, a structured nationwide approach involving international centers of excellence would be needed to improve selection of patients with LAPC for surgical resection following induction therapy.
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Journal, Combination therapy, IO biomarker: FOLFIRINOX chemotherapy modulates the peripheral immune landscape in pancreatic cancer: Implications for combination therapies and early response prediction. (Pubmed Central) - Dec 18, 2023
FOLFIRINOX has immunomodulatory effects, providing a foundation for clinical trials exploring immune-based combination therapies that harness the immune system to treat pancreatic cancer. In addition, several plasma proteins hold potential as circulating predictive biomarkers for early prediction of FOLFIRINOX response in patients with pancreatic cancer.
- || Loqtorzi (toripalimab) / Shanghai Junshi Biosci, Coherus Biosci, Lenvima (lenvatinib) / Eisai, Merck (MSD)
P2 data, Clinical Trial,Phase II, Journal: Lenvatinib, toripalimab plus FOLFOX chemotherapy in hepatocellular carcinoma patients with extrahepatic metastasis: A biomolecular exploratory, phase II trial (LTSC). (Pubmed Central) - Dec 17, 2023
FOLFOX chemotherapy in combination with lenvatinib and toripalimab showed promising antitumor activity with manageable toxicities in advanced HCC with extrahepatic metastasis. AKR1C2+ and CFHR4+ hepatocyte subtypes may be predictive biomarkers of resistance to the combination therapy.
- | 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Retrospective data, Journal, Metastases: Lateral Pelvic Nodal Management and Patterns of Failure in Patients Receiving Short-Course Radiation for Locally Advanced Rectal Cancer. (Pubmed Central) - Dec 17, 2023
Boost to clinically positive lateral nodes is a safe approach in the setting of short course radiation and in those receiving nonoperative intent. See Video Abstract.
- || lunresertib (RP-6306) / Repare Therap
Trial completion date, Trial primary completion date: RP-6306 in Patients With Advanced Cancer (clinicaltrials.gov) - Dec 15, 2023
P2, N=78, Recruiting, Sponsor: Canadian Cancer Trials Group
- |||| Yutuo (zimberelimab) / Arcus Biosci, Gilead, domvanalimab (AB154) / Arcus Biosci, Gilead
Trial completion date, Trial primary completion date: STAR-221: A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body (clinicaltrials.gov) - Dec 15, 2023
P3, N=970, Recruiting, Sponsor: Arcus Biosciences, Inc.
- ||| Sulanda (surufatinib) / Hutchmed
Trial completion date, Trial primary completion date, Metastases: A Phase 3 Study to Evaluate Surufatinib Plus Toripalimab in the Treatment of Advanced Neuroendocrine Carcinoma (clinicaltrials.gov) - Dec 15, 2023
P3, N=194, Recruiting, Sponsor: Hutchison Medipharma Limited
See Video Abstract. Trial completion date: Nov 2023 --> May 2025 | Trial primary completion date: Jul 2023 --> May 2025
- ||| certepetide (LSTA1) / Lisata Therap
Enrollment change: BOLSTER: A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Dec 15, 2023
P2, N=80, Recruiting, Sponsor: Lisata Therapeutics, Inc.
Trial completion date: Nov 2023 --> May 2025 | Trial primary completion date: Jul 2023 --> May 2025 N=120 --> 80
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
New P3 trial, Metastases: Infusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and Apatinib for Advanced HCC (clinicaltrials.gov) - Dec 15, 2023
P3, N=192, Recruiting, Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- Clinical outcomes of frontline GemFLP in advanced urachal and non-urachal adenocarcinomas of the urinary tract: The MD Anderson Cancer Center (MDACC) experience. (Level 1, West Hall; Poster Bd # H15) - Dec 13, 2023 - Abstract #ASCOGU2024ASCO_GU_587;
Pts with disease control (CR, PR, or SD) have a clear survival benefit compared to non-responders. 1L GemFLP might offer chances at surgical consolidation after disease control for pts with regional node-positive only disease, with larger cohorts needed to confirm findings.
- leucovorin calcium / Generic mfg., hydroxocobalamin (vit B12) / Generic mfg.
Late Onset Cobalamin C Disease in an adolescent patient of Mixteco ancestry and response to treatment (Studio 105 (Sunset Center)) - Dec 13, 2023 - Abstract #WRMC2024WRMC_535;
Repeat neuropsychiatric evaluation showed improved processing speed and greater task persistence and effort. His lower extremity weakness and gait continued to improve, being able to ambulate with minimal assistance.